Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide + fluorouracil + paclitaxel + docetaxel
- Development stage
- Unknown
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen composed of five cytotoxic agents: doxorubicin (an anthracycline antibiotic), cyclophosphamide (an alkylating agent), fluorouracil (a pyrimidine analog antimetabolite), paclitaxel and docetaxel (both taxanes). These drugs are used in various combinations for the treatment of breast cancer. Doxorubicin intercalates DNA and inhibits topoisomerase II; cyclophosphamide crosslinks DNA; fluorouracil inhibits thymidylate synthase disrupting DNA synthesis; both paclitaxel and docetaxel stabilize microtubules preventing cell division. The regimens AC-T or TAC are commonly used in adjuvant or metastatic breast cancer settings[1][3][8]. The addition of these agents improves response rates but increases toxicity.
- Other names
- AC-T (for doxorubicin, cyclophosphamide, and paclitaxel)TAC (for docetaxel, doxorubicin, and cyclophosphamide)FAC (for fluorouracil, doxorubicin, and cyclophosphamide)
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNATS (Thymidylate synthase)
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide + fluorouracil + paclitaxel + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide + fluorouracil + paclitaxel + docetaxel.